FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is pharmaceutical composition for treating psoriasis, which includes, at least, one excipient and active agents counted per total composition weight: clobetasol propionate: 0.05-5%, minoxydyl: 0.05-7% and 11-alfa-hydroxyprogesteron: 0.05-12%. Composition can also include other excipients, vitamins and/or mineral compounds. It is demonstrated: 11-alfa-hydroxyprogesteron reduces grease-secretion on affected region, which increases action of other active agents. Efficiency of composition is manifested 2-4 days after beginning of treatment, it does not change skin colour, side effects are manifested in light degree.
EFFECT: composition retards accelerated growth of skin cells, as well as suppresses development of other abnormal phenomena developing in case of psoriasis vulgaris.
15 cl, 2 ex
